NDAINTRAMUSCULAR, INTRAVENOUSINJECTABLE
Approved
Nov 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
5/8 — Partial
INVANZ (ertapenem sodium) by Merck & Co. is 12. First approved in 2001.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INVANZ (ertapenem sodium) is a carbapenem antibiotic administered intravenously or intramuscularly that works by inhibiting bacterial cell wall synthesis. It is indicated for serious infections caused by susceptible gram-positive, gram-negative, and anaerobic bacteria in adult and pediatric patients. The drug exhibits non-linear pharmacokinetics with concentration-dependent plasma protein binding and demonstrates approximately 90% bioavailability via intramuscular administration.
$0.014BPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with minimal Part D claims (38 in 2023), signaling a contracting brand team focused on transition planning and cost-mitigation strategies.
Mechanism of Action
12.1 Mechanism of Action Ertapenem sodium is a carbapenem antibiotic [see ]. 12.3 Pharmacokinetics Average plasma concentrations (mcg/mL) of ertapenem following a single 30-minute infusion of a 1 g intravenous (IV) dose and administration of a single 1 g intramuscular (IM) dose in healthy young…
Worked on INVANZ at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.